Immunotherapy

Patients with non-small cell lung cancer and a KRAS G12C genetic mutation may benefit from treatment with an inhibitor targeting that mutation, although more research is needed to learn why more patients are not responding to the drug.

Even with all the recent advances in targeted therapies and immunotherapy drugs, patients with non-small cell lung cancer still need more treatment options. Although it’s early, cell-based therapies have shown some promise, with more research underway.

Antibiotics, corticosteroids and proton pump inhibitors could cause negative impacts on survival in patients with non-small cell lung cancer who are receiving treatment with Keytruda.

Rozlytrek continues to demonstrate clinical benefit for patients with ROS1 fusion-positive non-small cell lung cancer, which includes patients with central nervous system metastases.

Chimeric antigen receptor (CAR)-T cell therapy is becoming more widely available, with two drugs approved to treat specific blood cancers and more being investigated in clinical trials across cancer types. Here’s what patients need to know if they’re considering treatment with one of these novel immunotherapies.

In an interview with CURE®, Dr. Trisha Wise-Draper discusses new findings that show an increased mortality risk for patients with cancer receiving systemic treatments who subsequently contracted COVID-19.

More than half of the patients (61%) admitted to either the hospital or ICU were discharged and 12% remained in the hospital. Nine patients had died by the time data collection was cut off for this study.

Immunotherapy is a wonderful testament to the benefits that arise from our growing understanding of the incredibly intricate human immune system.

In the 2020 special issue of CURE on Immunotherapy, we take a look at how the field of immunotherapy continues to grow despite challenges from the COVID-19 pandemic.

Cutting-edge medical information and first-person accounts empower patients to evaluate immunotherapy as a treatment option, one organization attests.

Across cancer types, a unique immune-stimulating treatment called tumor-infiltrating lymphocyte therapy produces durable remissions that could last for decades.

A new tool analyzes patterns of RNA expressed from genes, pinpointing more patients with cancer who can benefit from immunotherapies and targeted drugs.

New immunotherapy combinations aim to turbocharge the immune system’s attack against cancer.

Immunotherapy with Keytruda shows promise in advanced uncommon cancers in which new treatment options are needed.

Going in for an infusion amid the coronavirus pandemic with a possible "symptom" of COVID-19 and wondering what risks lie ahead.

Researchers from China examined the impact that coronavirus has on patients who are receiving anti-cancer treatment.

Combining immunotherapies with chemotherapy has shown improved survival in patients with extensive-stage small cell lung cancer.

Patients with relapsed and resistant diffuse large B-cell lymphoma can look to new treatments beyond tried-and-true chemotherapy.

The combination of Keytruda plus chemoradiotherapy induced a ‘promising’ 12-month progression-free survival rate in patients with locally advanced non-small cell lung cancer.

Treatment for patients with bladder cancer is moving away from VEGF-targeted therapies toward immune checkpoint inhibition, according to one expert.

Top Translational Grants Named for Former CEO Nick Valvano, Former Scientific Advisory Committee Chair Dr. Robert Bast.

One cancer survivor details how her immunotherapy changed her cancer journey for the better, and how ongoing trials of immunotherapy are looking to change the cancer landscape for the better.